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Ischaemic heart disease (IHD) is a major cause of mortality and 
morbidity worldwide, especially in industrialised countries.1 In 
the Western Cape, IHD was the leading cause of mortality in the 
cardiovascular category in 2000 and has consistently appeared in 
the top five causes of mortality since.2 In keeping with international 
studies, mortality from IHD was higher in males than females.3
While primary prevention of IHD is considered the ideal, mortality 
and morbidity in patients presenting with acute myocardial infarction 
(AMI) can be reduced with early interventions such as fibrinolysis 
or percutaneous coronary intervention (PCI).4 Many studies have 
shown that early PCI is more advantageous in reducing mortality 
from re-infarction and the need for a coronary artery bypass graft 
(CABG) than fibrinolytic drug therapy.5-7 In the Western Cape, PCI 
is limited to two tertiary hospitals, making fibrinolytic drug therapy 
the more accessible form of treatment for ST elevation myocardial 
infarction (STEMI) patients.
Early administration of fibrinolytic therapy improves patient 
outcomes in terms of limiting infarct size, so preserving left ventricular 
function.8,9 This is achieved by re-establishing the patency of the 
occluded coronary vessel.8-10 Maximal benefit from fibrinolysis is 
seen when the fibrinolytic is given within the first hour of symptom 
onset.11,12
Delaying fibrinolytic therapy by one hour increases the hazard 
ratio of death by 20%, (95% confidence interval (CI) 7 - 88), and a 
delay of 30 minutes or more can reduce the average life expectancy by 
one year.13 Minimising the time delay between onset of symptoms to 
definitive treatment improves mortality and morbidity.
The period between the onset of symptoms to administration of 
fibrinolytic therapy can be divided as follows:
•	 interval between onset of symptoms to seeking medical attention
•	 period taken to transport patient to definitive care
•	 interval between arrival at hospital to initiation of fibrinolytics 
(door-to-needle time).
The first two components can be improved by public education 
and developing efficient pre-hospital systems. The door-to-needle 
time is the one in-hospital factor that can be addressed by medical 
practitioners.
The American Heart Association/American College of Cardiology 
(AHA/ACC) guidelines recommend a door-to-needle time of 
30 minutes or less for administration of fibrinolytics for STEMI 
patients.14 Compliance with this time period is considered a marker 
of quality of care.15
No data on the door-to-needle time in the emergency centres (ECs) 
of public hospitals in Cape Town were found. We aimed to determine 
the current door-to-needle time for fibrinolytic administration in 
patients with STEMIs, determine patient demographics, and assess 
factors that could influence the door-to-needle time.
Methods
A retrospective audit was conducted of all patients who received 
thrombolytics for AMI in the ECs of 3 hospitals in Cape Town from 
January 2008 to July 2010.
Inclusion criteria
All adult patients with acute ST segment elevation, new onset left 
bundle branch block (LBBB), or posterior infarct on electrocardiogram 
(ECG) meeting AHA/ACC criteria for thrombolysis, who received 
thrombolytics in the above ECs.
Patients excluded
Patients who received pre-hospital thrombolysis or those thrombolysed 
at other centres before referral; patients receiving thrombolysis for 
conditions other than myocardial infarction; cases where patient files 
were missing from central records; and cases with incomplete data such 
that door-to-needle time could not be calculated.
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Objectives. To determine the current door-to-needle time for the 
administration of fibrinolytics for acute myocardial infarction 
(AMI) in emergency centres (ECs) at three hospitals in Cape Town, 
and to compare it with the American Heart Association/American 
College of Cardiology (AHA/ACC) recommendation of 30 minutes 
as a marker of quality of care.
Methods. A retrospective review of case notes from January 
2008 to July 2010 of all patients receiving thrombolytics for AMI 
in the ECs of three Cape Town hospitals. The total door-to-needle 
time was calculated and patient demographics and presentation, 
physician qualification, clinical symptomology and reasons for 
delays in thrombolytic administration were analysed.
Results. A total of 372 patients with acute ST elevation myocardial 
infarction (STEMI) were identified; 161 patients were eligible 
for the study. The median door-to-needle time achieved was 54 
minutes (range 13 - 553 mins). A door-to-needle time of 30 minutes 
or less was achieved in 33 (20.5%) patients; 51.3% of the patients 
arrived by ambulance; 34% of patients had a pre-hospital 12-lead 
ECG; and 88.8% had typical symptoms of myocardial infarction. 
Medical officers administered thrombolytics to 44.7% of the 
patients. The predominant infarct location on ECG was inferior 
(55.9%).
Conclusion. A significant number of patients were not 
thrombolysed within 30 minutes of presentation. The lack of senior 
doctors, difficulty interpreting ECGs, atypical presentations and 
EC system delays prolonged the door-to-needle time in this study.
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Data collection
Eligible patients were identified from the EC registry. Case notes 
were reviewed by a single observer. The required data were 
extracted onto a standardised data collection form. The quality 
of data collected was dependent on the availability and accuracy 
of the case notes. Incomplete documentation, and illegible and 
ambiguous notes were identified.
The following data were collated and analysed: patient 
demographics; transport mode to hospital; pre-hospital ECG 
acquisition, either by emergency medical services (EMS) or the 
primary care facility staff; and time of day (working hours v. after 
hours) when patient arrived. Working hours was defined as 08h00 
to 17h00, and after hours between 17h00 and 08h00 the next day. 
No distinction was made between weekdays or weekends as the 
ECs had similar staffing and dynamics on both weekdays and 
weekends.
The following time intervals were calculated:
•	 earliest time of presentation to hospital (taken from EMS records 
or admission chart) to time of triage
•	 time from triage to ECG acquisition
•	 time from ECG acquisition to actually commencing thrombolytics.
The sum of the above time intervals constitutes the total door-to-
needle time.
All data were collected and transferred onto an Excel spreadsheet 
program. Simple descriptive statistics were used to describe the 
median time to triage, triage to ECG, ECG to fibrinolytic, and 
total door-to-needle times. Subgroup analysis was performed for 
determining prevalence of STEMIs fibrinolysed based on gender and 
age group; anatomical localisation of myocardial infarction; transport 
times; and level of experience of treating physician. The symptoms on 
presentation were also assessed. Typical symptoms were defined as an 
acute onset of chest pain with radiation to the left arm, neck or jaw 
with associated autonomic symptoms (sweating, nausea or vomiting). 
Statistical analysis was undertaken using Microsoft Excel (Microsoft, 
Richmond, USA), EpiCalc 2000 (Brixton Books, London, UK) and 
STATA (Stata Corp, College St, USA).
Ethics
Ethics approval was granted by the University of Cape Town, Faculty 
of Health Sciences Ethics Committee (REC REF 539/2009).
Results
From the EC registries of the 3 hospitals under study, a total of 372 
patients with STEMI were identified. The final number included in 
the study was 161. The consort diagram is shown as Fig. 1. Table 1 
lists the demographic variables.
The largest category (39.8%; 95% CI 32.1 - 47.4) of patients 
thrombolysed were in the 45 - 54-year-old age group, with the next 
largest in the 55 - 64-year-old age group. A door-to-needle time ≤30 
minutes was achieved in 33 (20.5%) patients. Table 2 shows the door-
to-needle time of the entire study.The median door-to-needle time 
was 54 minutes (range 13 - 553). Table 3 depicts the median time 
achieved for each of the intervals studied.
Of the patients, 44.7% (CI 36.9 - 52.7) were seen and given fibrinolysis 
by medical officers, with 34.8 % (CI 27.5 - 42.7) treated by emergency 
medicine registrars. The remaining patients were seen and treated by 
interns (4.4%; CI 1.9 - 9.1), junior community service doctors (14.9%; CI 
9.8 - 21.6), and emergency physicians (1.2%; CI 6.2- 14.9).
The predominant infarct location on ECG was inferior (55.9%; 
CI 47.9 - 63.6), followed by anterior (38.5%; CI 31.0 - 46.5). A door-
to-ECG time <10 minutes was achieved in 41.2% of patients. Table 
4 lists the influence of mode of arrival, time of arrival, symptoms, 
pre-hospital ECG and level of experience of treating doctor on the 
door-to-needle time.
The reasons for delays in initiating fibrinolytic therapy were 
documented by the attending doctor in 70 of the 161 cases (43.5%). 
Delays resulted from:
•	 The attending doctor seeking advice from the senior doctor in 
the EC or the Internal Medicine registrar before commencing 
fibrinolysis. The reason for consulting the senior was not 
documented. (28.6%).
•	 Difficulty in interpreting the ECG (18.6%).
•	 Patients presenting with atypical symptoms, hence delaying the 
diagnosis of AMI (12.9%).
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Fig. 1. Patient profile.
Table 1. Demographic variables
Demographic variable Median (range) N% (95% CI)
Median age (yrs) 54 (31 - 84)
Sex
Male 66.5 (58.5 - 73.6)
Female 33.5 (26.4 - 41.4) 
Mode of arrival
Ambulance 51.2 (43.2 - 59.2)
Walk-in 48.8 (40.8 - 56.7)
Time of arrival
Working hours 52.2 (39.9 - 55.8)
After hours 47.8 (44.2 - 60.1)
Pre-hospital ECG 33.9 (26.8 - 41.9)
Median pain-to-arrival time 
(mins) 192.5 (10 - 765)
Symptomatology
Typical 88.8 (82.7 - 93.1)
Atypical 11.2 (6.9 - 17.3)
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•	 Patients going into cardiac arrest and requiring cardiopulmonary 
resuscitation (CPR) before thrombolytic therapy could be 
commenced (11.4%).
•	 Patients presenting with hypertension (systolic blood pressure 
>180 mmHg), which is a relative contra-indication to fibrinolysis, 
hence blood pressure control was needed before administration of 
fibrinolytics (7.1%).
•	 Patients presenting during change of shifts for nurses or doctors 
were not attended to timously (7.1%).
•	 Delays in obtaining a chest X-ray (4.3%).
•	 Fibrinolytic agent not available in the EC, and a nurse had to fetch 
it from the pharmacy (4.3%).
•	 Waiting for results of cardiac enzymes, non-availability of intensive 
care beds, and equipment (infusion pump) failure accounted for 
the remainder of the delays (5.7%).
Discussion
Minimising the time between the onset of an AMI to initiation 
of a reperfusion strategy is important to improve prognosis and 
survival.11,12 In this study, less than a third of patients with STEMI 
received thrombolytics within the prescribed time interval of 30 
minutes. The median door-to-needle time of 54 minutes was higher 
than the 45 minutes recorded by North American and European 
hospitals;16-19 it was comparable with studies done in the Middle East, 
Pakistan and India, and a study in Vancouver.20-23 However, in some 
of these studies, thrombolysis was given in the intensive care unit 
(ICU) and not in the EC, thereby prolonging door-to-needle times. 
The number of patients thrombolysed within 30 minutes was lower 
than other contemporary studies, although some of them had smaller 
sample sizes.16,17,20-23
A key modifiable factor contributing to prolonged door-to-needle 
times was the need for senior review or advice on ECG interpretation 
that contributed to almost half of the documented delays in 
thrombolysis. Other studies also identified delay in diagnosis or 
ECG interpretation as a contributory factor to prolonged door-to-
needle times.20,21 In our setting, physician experience may also be a 
contributory factor. Medical officers working in Cape Town public 
sector hospitals have variable levels of experience and training. 
Emergency medicine is also a new speciality in South Africa, 
with emergency medicine registrars at different points in their 
training. Although medical officers had shorter median door-to-
needle times than emergency medicine (EM) registrars, they had a 
wider range than EM registrars. ECG interpretation and the decision 
to thrombolyse are more reliable in more experienced doctors than 
junior doctors.24 Other reasons for seeking senior advice could not be 
reliably identified from the case notes.
Patients presenting with atypical symptoms or with undifferentiated 
chest pain require an ECG to diagnose a STEMI. A door-to-ECG 
time <10 minutes has been recommended by the AHA/ACC for all 
patients with chest pain or symptoms suggestive of ACS.14 Prolonged 
door-to-ECG time leads to an increased risk of adverse clinical 
outcomes in patients with a STEMI.25 Our study gave a median 
door-to-ECG time of 13 minutes (range 1 - 402 mins), with <50% of 
patients having an ECG within 10 minutes.
The three hospitals studied have busy ECs often burdened with 
overcrowding that can prolong the door-to-triage sub-interval of the 
door-to-needle time. The Western Cape uses the South African Triage 
Scale consisting of two parts which has been validated in community 
health centres and hospitals:26 (i) a triage early-warning score which 
involves taking the patients’ vitals, and assessing the patients’ level of 
consciousness, mobility and evidence of trauma; and (ii) a discriminator 
list which allows the ‘triager’ to upgrade a patient to a higher colour 
category. Chest pain is part of this discriminator list and upgrades 
all chest-pain patients to at least an orange category. All orange/red 
patients should be attended to immediately or within 10 minutes of 
presentation.26 The median door-to-triage time was 6 minutes. We did 
not measure the time from triage to first physician contact owing to the 
poor record-keeping of this time in the patient records.
The organisational ability and patient flow characteristics of a 
hospital also influence door-to-needle times. We identified many 
factors that hindered patient flow. Delays in obtaining X-rays, 
patients arriving during nurse and doctor handovers not being 
attended to timously, and prolonged door-to-ECG times, all suggest 
shortcomings in patient flow pathways.
The ECG to commencement of fibrinolytic time interval 
constituted the longest delay in the door-to-needle time and is 
attributed to patient and physician factors. Some patients went into 
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Table 2. Door-to-needle time in minutes
Door-to-needle time (mins) % (n); N=161
Within 30 mins 20.5 (33)
31 - 60 mins 37.9 (61)
61 - 90 mins 26.7 (43)
>90 mins 14.9 (24)
Table 3. Median time achieved for each interval in minutes
Time interval Median time (range) (mins)
Door to triage 6 (0 - 157)
Triage to ECG 2 (0 - 245)
Door to ECG 13 (1 - 402)
ECG to fibrinolytic 38 (4 - 262)
Door-to-needle time 54 (13 - 553)
Table 4. Comparison of median door-to-needle times
Variable
Median door-to-needle 
time (range) (mins)
Mode of arrival
Ambulance 53 (10 - 553)
Walk in 50 (10 - 270)
Time of arrival
Working hours 53 (15 - 553)
After hours 54.5 (13 - 457)
Symptomatology
Typical 53 (13 - 245)
Atypical 65 (17 - 553)
Prehospital ECG
Yes 50 (15 - 553)
No 55 (13 - 270)
Level of experience of doctor
Medical officer 50 (17 - 553)
Emergency medicine registrar 55 (15 - 195)
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cardiac arrest and required cardiopulmonary resuscitation. Others 
presented with hypertension, which required blood pressure lowering 
before commencing lysis.
Pre-hospital factors prolonging door-to-needle times included 
patient demographics, pre-hospital transport delays and time of 
presentation to hospital. The AMI Quebec Study investigated some of 
these factors and found that older patients had a decreased likelihood 
of getting timous reperfusion therapy;16 possible reasons were that 
elderly patients had more atypical symptoms and an increased risk 
of complications from fibrinolysis.27,28 Patients presenting after hours 
had longer door-to-needle times, probably owing to fewer staff being 
available after hours.16 In another study, the time to fibrinolyisis 
did not differ much by patient arrival time.29 Patient factors such 
as denial of symptoms and delays in activating EMS also contribute 
to delayed fibrinolysis.30 Pre-hospital transport delays secondary to 
resource limitations, distance to hospital with reperfusion capability, 
and traffic delays are other factors contributing to prolonged times 
to fibrinolysis.30,31
Although the present study suggested that shorter median door-
to-needle times were achieved in patients who arrived with their own 
transport, presented during working hours, had typical symptoms of 
AMI and had a pre-hospital ECG, the sample size was too small to 
draw definite conclusions.
Most quality improvement studies suggest a team-based approach 
to improving the time-to-reperfusion therapy for MI patients.16,17,31 In 
our setting, quality improvement audits must focus on in-hospital and 
pre-hospital factors. Most of the in-hospital reasons that we identified 
for delays in door-to-needle times could be improved by efficient 
triaging, early ECG acquisition for at-risk patients, EC physician 
training, the presence of a senior doctor/physician on the floor or 
being readily available telephonically, knowing the population profile, 
and having a low threshold for investigating those with atypical 
symptoms. Other in-hospital organisational strategies include close 
co-operation between hospital administration, emergency centre 
staff and auxiliary services to enhance patient flow, and interpretation 
of the ECG by the most competent physician in the EC. The ready 
availability of fibrinolytic stock in the EC, and rapid nurse-driven 
administration of fibrinolytics once diagnosis has been made, should 
be encouraged. Keeping a provincial registry of all AMI presentations 
will aid data analysis and protocol development.
Pre-hospital quality improvement in our setting should include 
education of the public to recognise signs and symptoms of AMI, and 
early activation of emergency services or accessing the nearest health 
facility. An integrated local EMS chest pain protocol supporting rapid 
diagnosis and pre-hospital ECG acquisition should be developed.
As international quality improvement audits have shown significant 
decreases in door-to-needle times, similar audits need to be done in 
Cape Town hospitals to improve door-to-needle time and hence reduce 
mortality and morbidity from STEMI.17 Developing a standardised 
protocol and checklist for thrombolysis would be beneficial.
Limitations
This was a retrospective chart review that relied on the accuracy 
of data recorded; 24.5% of patient files could not be located from 
the central records of the hospitals, and 15% of the files located 
had incomplete documentation or missing notes and could not be 
included. Times recorded are dependent on the attending doctor 
or nurse, which could have influenced the accuracy of our findings.
Conclusion
Only 20.5% (95% CI 14.71 - 27.72) of patients with STEMI met the 
AHA/ACC guideline of receiving fibrinolytics within a 30-minute 
door-to-needle time. This is below international standards of greater 
than 40%.22,23There are several factors contributing to a prolonged 
door-to-needle time that need to be addressed by creating an 
efficient, team-based approach to managing these patients. A repeat 
audit is needed once hospital systems are changed to determine if 
there is an improvement in the door-to-needle time.
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